 Mary Yang
Concepts (245)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 20 | 2018 | 215 | 2.570 |
Why?
| | Systems Biology | 5 | 2018 | 32 | 2.040 |
Why?
| | Algorithms | 22 | 2022 | 625 | 2.000 |
Why?
| | Single-Cell Analysis | 3 | 2024 | 63 | 1.690 |
Why?
| | Gene Expression Profiling | 14 | 2024 | 1025 | 1.650 |
Why?
| | Promoter Regions, Genetic | 8 | 2010 | 465 | 1.510 |
Why?
| | Transcriptome | 5 | 2022 | 313 | 1.150 |
Why?
| | Gene Regulatory Networks | 8 | 2021 | 106 | 1.140 |
Why?
| | Artificial Intelligence | 13 | 2022 | 96 | 1.100 |
Why?
| | Sequence Analysis, RNA | 3 | 2024 | 88 | 1.000 |
Why?
| | Genomics | 6 | 2018 | 279 | 0.990 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2022 | 45 | 0.960 |
Why?
| | Breast Neoplasms | 3 | 2024 | 1201 | 0.960 |
Why?
| | Mutation | 5 | 2024 | 1280 | 0.950 |
Why?
| | Proteins | 6 | 2010 | 339 | 0.910 |
Why?
| | Quantitative Structure-Activity Relationship | 3 | 2008 | 32 | 0.880 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 222 | 0.820 |
Why?
| | Pattern Recognition, Automated | 5 | 2009 | 40 | 0.760 |
Why?
| | Sequence Analysis, Protein | 3 | 2009 | 19 | 0.690 |
Why?
| | Oligonucleotide Array Sequence Analysis | 8 | 2009 | 405 | 0.660 |
Why?
| | Ovarian Neoplasms | 2 | 2016 | 450 | 0.610 |
Why?
| | Conserved Sequence | 2 | 2017 | 56 | 0.600 |
Why?
| | Neurons | 1 | 2021 | 452 | 0.600 |
Why?
| | Sequence Analysis, DNA | 5 | 2009 | 226 | 0.600 |
Why?
| | Models, Chemical | 2 | 2008 | 64 | 0.590 |
Why?
| | Lung Neoplasms | 3 | 2018 | 601 | 0.570 |
Why?
| | Genome, Human | 5 | 2018 | 109 | 0.570 |
Why?
| | Drug Design | 2 | 2008 | 119 | 0.560 |
Why?
| | Protein Interaction Mapping | 1 | 2016 | 37 | 0.530 |
Why?
| | Brain | 3 | 2018 | 1319 | 0.480 |
Why?
| | Genetic Research | 1 | 2014 | 4 | 0.480 |
Why?
| | Ankyrins | 2 | 2010 | 9 | 0.450 |
Why?
| | Humans | 35 | 2024 | 50503 | 0.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 833 | 0.430 |
Why?
| | MicroRNAs | 5 | 2018 | 344 | 0.420 |
Why?
| | Genetic Predisposition to Disease | 4 | 2018 | 511 | 0.400 |
Why?
| | Models, Molecular | 3 | 2008 | 334 | 0.400 |
Why?
| | Transcription Factor TFIID | 2 | 2010 | 4 | 0.380 |
Why?
| | Biological Evolution | 2 | 2009 | 32 | 0.380 |
Why?
| | Chromosome Mapping | 2 | 2009 | 153 | 0.370 |
Why?
| | Sequence Alignment | 2 | 2008 | 119 | 0.370 |
Why?
| | Genome | 2 | 2009 | 65 | 0.360 |
Why?
| | Transcription Factors | 2 | 2021 | 565 | 0.360 |
Why?
| | Spherocytosis, Hereditary | 1 | 2010 | 14 | 0.360 |
Why?
| | Genetic Techniques | 1 | 2010 | 13 | 0.350 |
Why?
| | Software | 3 | 2009 | 276 | 0.340 |
Why?
| | Gene Expression Regulation | 3 | 2021 | 955 | 0.330 |
Why?
| | Sequence Analysis | 1 | 2009 | 8 | 0.330 |
Why?
| | Evolution, Molecular | 3 | 2010 | 95 | 0.330 |
Why?
| | Congresses as Topic | 1 | 2009 | 48 | 0.320 |
Why?
| | Neoplasms | 6 | 2022 | 1251 | 0.320 |
Why?
| | Neoplasm Proteins | 3 | 2008 | 320 | 0.310 |
Why?
| | Databases, Genetic | 6 | 2018 | 88 | 0.310 |
Why?
| | Vertebrates | 1 | 2008 | 8 | 0.300 |
Why?
| | Open Reading Frames | 2 | 2018 | 47 | 0.300 |
Why?
| | Artifacts | 1 | 2009 | 54 | 0.300 |
Why?
| | Molecular Sequence Annotation | 2 | 2018 | 27 | 0.300 |
Why?
| | Mammals | 1 | 2008 | 50 | 0.290 |
Why?
| | RNA | 2 | 2024 | 163 | 0.290 |
Why?
| | Pharmaceutical Preparations | 1 | 2008 | 76 | 0.290 |
Why?
| | Protein Conformation | 5 | 2010 | 162 | 0.260 |
Why?
| | Catechin | 2 | 2016 | 13 | 0.250 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 778 | 0.250 |
Why?
| | Disease Progression | 2 | 2018 | 829 | 0.250 |
Why?
| | Base Sequence | 5 | 2010 | 639 | 0.250 |
Why?
| | Cluster Analysis | 2 | 2024 | 219 | 0.240 |
Why?
| | Computer Simulation | 4 | 2008 | 279 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 76 | 0.220 |
Why?
| | Probability | 1 | 2024 | 164 | 0.220 |
Why?
| | Prognosis | 3 | 2024 | 1978 | 0.210 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2022 | 17 | 0.210 |
Why?
| | CpG Islands | 2 | 2016 | 108 | 0.200 |
Why?
| | Organogenesis | 1 | 2021 | 2 | 0.200 |
Why?
| | Neural Stem Cells | 1 | 2021 | 26 | 0.190 |
Why?
| | ROC Curve | 3 | 2018 | 226 | 0.190 |
Why?
| | Animals | 10 | 2017 | 13124 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2016 | 475 | 0.180 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 41 | 0.180 |
Why?
| | Databases, Protein | 3 | 2010 | 28 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 204 | 0.180 |
Why?
| | Female | 10 | 2024 | 27081 | 0.180 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 269 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2022 | 316 | 0.170 |
Why?
| | Amino Acid Sequence | 4 | 2010 | 574 | 0.170 |
Why?
| | Transcription Initiation Site | 2 | 2010 | 13 | 0.170 |
Why?
| | Receptor, Melatonin, MT2 | 1 | 2018 | 1 | 0.160 |
Why?
| | Neoplasm Staging | 2 | 2018 | 746 | 0.160 |
Why?
| | Area Under Curve | 1 | 2018 | 179 | 0.150 |
Why?
| | Amyloid beta-Peptides | 1 | 2018 | 66 | 0.150 |
Why?
| | Forkhead Transcription Factors | 1 | 2018 | 110 | 0.150 |
Why?
| | Diabetes Complications | 1 | 2018 | 116 | 0.150 |
Why?
| | Neoplastic Stem Cells | 1 | 2018 | 98 | 0.150 |
Why?
| | Peptide Fragments | 1 | 2018 | 209 | 0.150 |
Why?
| | Protein Structure, Tertiary | 2 | 2008 | 245 | 0.140 |
Why?
| | Protein Isoforms | 1 | 2017 | 116 | 0.140 |
Why?
| | RNA, Messenger | 2 | 2014 | 1089 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 415 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2018 | 158 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2018 | 119 | 0.140 |
Why?
| | Autistic Disorder | 1 | 2018 | 126 | 0.140 |
Why?
| | Survival Analysis | 1 | 2018 | 661 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-myb | 1 | 2016 | 8 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2016 | 122 | 0.130 |
Why?
| | Models, Biological | 3 | 2008 | 716 | 0.130 |
Why?
| | Gastric Mucosa | 1 | 2016 | 48 | 0.130 |
Why?
| | Models, Statistical | 4 | 2009 | 226 | 0.130 |
Why?
| | Transcription, Genetic | 3 | 2018 | 361 | 0.120 |
Why?
| | Coronary Disease | 1 | 2016 | 152 | 0.120 |
Why?
| | Binding Sites | 3 | 2010 | 362 | 0.120 |
Why?
| | Camellia sinensis | 1 | 2014 | 4 | 0.120 |
Why?
| | Alzheimer Disease | 1 | 2018 | 316 | 0.120 |
Why?
| | Inflammation | 2 | 2016 | 610 | 0.120 |
Why?
| | Anticarcinogenic Agents | 1 | 2014 | 32 | 0.120 |
Why?
| | Triazines | 1 | 2014 | 24 | 0.120 |
Why?
| | Up-Regulation | 1 | 2016 | 446 | 0.120 |
Why?
| | Polyphenols | 1 | 2014 | 33 | 0.110 |
Why?
| | Consensus Sequence | 2 | 2010 | 24 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1172 | 0.110 |
Why?
| | Environmental Pollutants | 1 | 2014 | 102 | 0.110 |
Why?
| | Stomach Neoplasms | 1 | 2016 | 189 | 0.100 |
Why?
| | 5' Untranslated Regions | 2 | 2010 | 25 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2016 | 397 | 0.100 |
Why?
| | Least-Squares Analysis | 2 | 2009 | 40 | 0.100 |
Why?
| | Base Composition | 2 | 2009 | 29 | 0.100 |
Why?
| | Sequence Homology, Nucleic Acid | 2 | 2010 | 46 | 0.100 |
Why?
| | Signal Transduction | 4 | 2016 | 1624 | 0.090 |
Why?
| | DNA-Binding Proteins | 2 | 2016 | 418 | 0.090 |
Why?
| | Rats | 1 | 2017 | 3292 | 0.090 |
Why?
| | Time Factors | 1 | 2017 | 2935 | 0.090 |
Why?
| | Genetic Diseases, Inborn | 2 | 2008 | 20 | 0.090 |
Why?
| | K562 Cells | 1 | 2010 | 40 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2016 | 3226 | 0.090 |
Why?
| | Models, Genetic | 2 | 2008 | 172 | 0.090 |
Why?
| | Obesity | 1 | 2018 | 1121 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2010 | 40 | 0.090 |
Why?
| | DNA | 2 | 2010 | 535 | 0.090 |
Why?
| | Protein Binding | 2 | 2010 | 654 | 0.080 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 62 | 0.080 |
Why?
| | Sample Size | 1 | 2009 | 39 | 0.080 |
Why?
| | TATA Box | 1 | 2008 | 9 | 0.080 |
Why?
| | RNA Polymerase II | 1 | 2008 | 12 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 859 | 0.080 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2008 | 36 | 0.080 |
Why?
| | Principal Component Analysis | 1 | 2008 | 54 | 0.080 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 64 | 0.080 |
Why?
| | Middle Aged | 4 | 2018 | 12611 | 0.080 |
Why?
| | Tumor Burden | 1 | 2008 | 130 | 0.070 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2008 | 44 | 0.070 |
Why?
| | DNA Repair | 1 | 2009 | 188 | 0.070 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2008 | 6 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 162 | 0.070 |
Why?
| | Mutagenicity Tests | 1 | 2008 | 42 | 0.070 |
Why?
| | Cushing Syndrome | 1 | 2008 | 11 | 0.070 |
Why?
| | Subcellular Fractions | 1 | 2008 | 33 | 0.070 |
Why?
| | False Positive Reactions | 1 | 2008 | 59 | 0.070 |
Why?
| | 14-3-3 Proteins | 1 | 2008 | 18 | 0.070 |
Why?
| | Markov Chains | 1 | 2008 | 30 | 0.070 |
Why?
| | Internet | 1 | 2010 | 259 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 71 | 0.070 |
Why?
| | Radiation Tolerance | 1 | 2008 | 84 | 0.070 |
Why?
| | Health Services Research | 1 | 2008 | 152 | 0.070 |
Why?
| | Research | 1 | 2008 | 106 | 0.070 |
Why?
| | Expressed Sequence Tags | 1 | 2007 | 8 | 0.070 |
Why?
| | Aged | 3 | 2016 | 9741 | 0.070 |
Why?
| | Multigene Family | 1 | 2007 | 54 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 61 | 0.070 |
Why?
| | Biomedical Research | 1 | 2009 | 244 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 213 | 0.060 |
Why?
| | Telomerase | 1 | 2006 | 26 | 0.060 |
Why?
| | Pheochromocytoma | 1 | 2006 | 36 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2008 | 332 | 0.060 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2006 | 51 | 0.060 |
Why?
| | Gene Expression | 1 | 2008 | 610 | 0.060 |
Why?
| | Mice | 3 | 2014 | 5687 | 0.060 |
Why?
| | Odds Ratio | 2 | 2016 | 551 | 0.060 |
Why?
| | Databases, Factual | 1 | 2008 | 673 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2018 | 1398 | 0.060 |
Why?
| | Risk Assessment | 1 | 2008 | 1270 | 0.050 |
Why?
| | China | 2 | 2016 | 90 | 0.050 |
Why?
| | Adult | 2 | 2016 | 13577 | 0.050 |
Why?
| | Drug Discovery | 1 | 2022 | 85 | 0.050 |
Why?
| | PubMed | 1 | 2018 | 13 | 0.040 |
Why?
| | Species Specificity | 2 | 2009 | 187 | 0.040 |
Why?
| | Axons | 1 | 2018 | 45 | 0.040 |
Why?
| | Cattle | 2 | 2009 | 205 | 0.040 |
Why?
| | Synapses | 1 | 2018 | 85 | 0.040 |
Why?
| | Microarray Analysis | 2 | 2008 | 70 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2008 | 5283 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2008 | 66 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 589 | 0.030 |
Why?
| | Receptors, Interleukin-1 Type II | 1 | 2016 | 2 | 0.030 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2016 | 6 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 36 | 0.030 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2016 | 34 | 0.030 |
Why?
| | Gene Frequency | 1 | 2016 | 97 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 160 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2016 | 72 | 0.030 |
Why?
| | Stomach | 1 | 2016 | 81 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2016 | 222 | 0.030 |
Why?
| | Nitrosamines | 1 | 2014 | 9 | 0.030 |
Why?
| | Genotype | 1 | 2016 | 533 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2018 | 985 | 0.030 |
Why?
| | Antioxidants | 1 | 2016 | 239 | 0.030 |
Why?
| | Neurotoxicity Syndromes | 1 | 2014 | 46 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2014 | 155 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 156 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 161 | 0.030 |
Why?
| | Carcinogens | 1 | 2014 | 196 | 0.030 |
Why?
| | Male | 4 | 2018 | 25907 | 0.030 |
Why?
| | Apoptosis | 1 | 2018 | 1097 | 0.030 |
Why?
| | NF-kappa B | 1 | 2014 | 315 | 0.030 |
Why?
| | Lung | 1 | 2016 | 504 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 1585 | 0.020 |
Why?
| | Cell-Free System | 1 | 2010 | 13 | 0.020 |
Why?
| | TATA-Box Binding Protein | 1 | 2010 | 6 | 0.020 |
Why?
| | Gene Library | 1 | 2010 | 41 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2010 | 67 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 206 | 0.020 |
Why?
| | Synteny | 1 | 2009 | 7 | 0.020 |
Why?
| | Animals, Domestic | 1 | 2009 | 8 | 0.020 |
Why?
| | RecQ Helicases | 1 | 2009 | 22 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2009 | 53 | 0.020 |
Why?
| | Mathematical Computing | 1 | 2008 | 7 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2008 | 33 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2010 | 540 | 0.020 |
Why?
| | Phylogeny | 1 | 2009 | 236 | 0.020 |
Why?
| | Biomedical Technology | 1 | 2008 | 8 | 0.020 |
Why?
| | Genetic Variation | 1 | 2009 | 207 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2008 | 68 | 0.020 |
Why?
| | Risk Factors | 1 | 2016 | 3724 | 0.020 |
Why?
| | Drug Therapy | 1 | 2008 | 47 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 180 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 147 | 0.020 |
Why?
| | Bacteria | 1 | 2008 | 218 | 0.020 |
Why?
| | Proteomics | 1 | 2009 | 314 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 572 | 0.020 |
Why?
| | Research Design | 1 | 2008 | 353 | 0.020 |
Why?
| | Adrenal Medulla | 1 | 2006 | 5 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 17 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2006 | 56 | 0.020 |
Why?
| | Logistic Models | 1 | 2008 | 900 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2008 | 957 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 1197 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2006 | 2242 | 0.010 |
Why?
| | Adolescent | 1 | 2006 | 6443 | 0.010 |
Why?
|
|
Yang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|